Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Valbenazine Ditosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 8,893Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Dysval

    02 4Ingrezza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Ingrezza

    Valbenazine

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Ingrezza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Neurocrine

    Valbenazine

    Main Therapeutic Indication : Neurology

    Currency : USD

    2020 Revenue in Millions : 993

    2019 Revenue in Millions : 753

    Growth (%) : 32

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Ingrezza

    Valbenazine

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Ingrezza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Neurocrine

    Valbenazine

    Main Therapeutic Indication : Neurology

    Currency : USD

    2021 Revenue in Millions : 1,082

    2020 Revenue in Millions : 993

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Ingrezza

    Valbenazine

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Ingrezza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Neurocrine

    Valbenazine

    Main Therapeutic Indication : Neurology

    Currency : USD

    2022 Revenue in Millions : 1,428

    2021 Revenue in Millions : 1,082

    Growth (%) : 32

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Dysval

    Valbenazine

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Dysval

    Japan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Mitsubishi Tanabe

    Valbenazine

    Main Therapeutic Indication : Neurology

    Currency : USD

    2022 Revenue in Millions : 24

    2021 Revenue in Millions : 0

    Growth (%) : New Launch in 2022

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Ingrezza

    Valbenazine

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Ingrezza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Neurocrine

    Valbenazine

    Main Therapeutic Indication : Neurology

    Currency : USD

    2023 Revenue in Millions : 1,836

    2022 Revenue in Millions : 1,428

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Dysval

    Valbenazine

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Dysval

    Japan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Mitsubishi Tanabe

    Valbenazine

    Main Therapeutic Indication : Neurology

    Currency : USD

    2023 Revenue in Millions : 28

    2022 Revenue in Millions : 24

    Growth (%) : 31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF